skip to Main Content
Issue Areas
Events
Publications
Connect With Us
About Us
2022 Snapshot
About IHP
Meet the Team
Contributing Authors
Search
Menu
Search
Submit
Issue Areas
Fostering Competitive Markets
Prescription drug prices continue to rise, threatening to make vital therapies unaffordable for many patients.
Learn more
Kaiser Permanente believes it is time for a new legal and policy landscape for drug pricing that rewards innovation and discovery, but also provides medicines at prices patients and the health care system can afford.
Featured content
Building a bigger table for a more equitable drug development system
Biosimilars at Kaiser Permanente
The Medicaid Drug Rebate Program and the impact of “best price” rules
How to save the patent system in 3 easy steps
The price Is wrong: Why we need to curb prices on biologics to protect patients
Our thoughts on HHS’s blueprint to lower drug prices: It’s time for a new legal and policy landscape
Reflections on high drug pricing in America: Where we are and where we’re headed
A provider and payor’s perspective on drug pricing
Events
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability
Addressing High Drug Pricing
Back To Top
Search
Submit